Acute Respiratory Distress Syndrome Clinical Trial
Official title:
Pilot Study on Cytokine Filtration in COVID-19 ARDS (CytokCOVID19)
Background: There are no proven therapies for COVID-19 infection. COVID-19 infects the
respiratory epithelium of the lower airways, causing widespread damage via cytopathic
effects, resulting in severe inflammation and Pneumonitis. High local and circulating levels
of cytokines, or cytokine storm, can lead to capillary leak syndrome, progressive lung
injury, respiratory failure and acute respiratory distress syndrome (ARDS).
Methods: This is a pilot randomized, controlled, uni-center study testing safety and efficacy
of cytokine filtration on patients with severe ARDS. Eligible patients will be randomized to
72 hours filtration or no filtration on top of the standard treatment for ARDS. Indications
for randomization are patients with moderate or severe ARDS with need of ventilation support
(either invasive or non-invasive), with inflammatory markers. The primary outcome will be
days on mechanical ventilation (MV) support. Secondary outcomes are 30-day mortality, ICU
days, need for extracorporeal membrane oxygenation (ECMO) support, duration of renal
replacement therapy (RRT) and catecholamine therapies, hospital length of stay, multi-organ
failure. All analysis will be done according to the intention to treat principle.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04384445 -
Zofin (Organicell Flow) for Patients With COVID-19
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05535543 -
Change in the Phase III Slope of the Volumetric Capnography by Prone Positioning in Acute Respiratory Distress Syndrome
|
||
| Completed |
NCT04695392 -
Restore Resilience in Critically Ill Children
|
N/A | |
| Terminated |
NCT04972318 -
Two Different Ventilatory Strategies in Acute Respiratory Distress Syndrome Due to Community-acquired Pneumonia
|
N/A | |
| Completed |
NCT04534569 -
Expert Panel Statement for the Respiratory Management of COVID-19 Related Acute Respiratory Failure (C-ARF)
|
||
| Completed |
NCT04078984 -
Driving Pressure as a Predictor of Mechanical Ventilation Weaning Time on Post-ARDS Patients in Pressure Support Ventilation.
|
||
| Completed |
NCT04451291 -
Study of Decidual Stromal Cells to Treat COVID-19 Respiratory Failure
|
N/A | |
| Not yet recruiting |
NCT06254313 -
The Role of Cxcr4Hi neutrOPhils in InflueNza
|
||
| Not yet recruiting |
NCT04798716 -
The Use of Exosomes for the Treatment of Acute Respiratory Distress Syndrome or Novel Coronavirus Pneumonia Caused by COVID-19
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT04909879 -
Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells for Non-COVID-19 Acute Respiratory Distress Syndrome
|
Phase 2 | |
| Terminated |
NCT02867228 -
Noninvasive Estimation of Work of Breathing
|
N/A | |
| Not yet recruiting |
NCT02881385 -
Effects on Respiratory Patterns and Patient-ventilator Synchrony Using Pressure Support Ventilation
|
N/A | |
| Completed |
NCT02545621 -
A Role for RAGE/TXNIP/Inflammasome Axis in Alveolar Macrophage Activation During ARDS (RIAMA): a Proof-of-concept Clinical Study
|
||
| Withdrawn |
NCT02253667 -
Palliative Use of High-flow Oxygen Nasal Cannula in End-of-life Lung Disease Patients
|
N/A | |
| Completed |
NCT02232841 -
Electrical Impedance Imaging of Patients on Mechanical Ventilation
|
N/A | |
| Completed |
NCT01504893 -
Very Low Tidal Volume vs Conventional Ventilatory Strategy for One-lung Ventilation in Thoracic Anesthesia
|
N/A | |
| Withdrawn |
NCT01927237 -
Pulmonary Vascular Effects of Respiratory Rate & Carbon Dioxide
|
N/A | |
| Completed |
NCT02889770 -
Dead Space Monitoring With Volumetric Capnography in ARDS Patients
|
N/A | |
| Completed |
NCT01680783 -
Non-Invasive Ventilation Via a Helmet Device for Patients Respiratory Failure
|
N/A | |
| Completed |
NCT02814994 -
Respiratory System Compliance Guided VT in Moderate to Severe ARDS Patients
|
N/A |